Background: To investigate the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) as prognostic biomarkers in intrahepatic cholangiocarcinoma (ICC) with a focus on viral hepatitis and liver status.
Methods: In this retrospective cohort study, patients from the institutional cancer registry with ICC from 2005 to 2016 were stratified by treatment group. Baseline inflammatory markers were dichotomized at the median. Overall survival (OS) was assessed via Kaplan-Meier curves and Cox proportional hazard models. Multiple patient, liver, and tumor factors were included in the multivariable analysis (MVA).
Results: About 131 patients (median age 65 years, 52% male, 76% Caucasian) had a median OS of 13.0 months. Resection/interventional oncology with/without systemic therapy had improved survival vs systemic therapy alone in Child-Pugh A patients (P < 0.01). In Child-Pugh B/C patients, this survival difference became nonsignificant (P = 0.22). Increased NLR and SII were associated with decreased survival (P < 0.01), while dichotomized PLR was not (P = 0.3). On MVA, increased NLR remained an independent prognostic factor (HR 1.6, P < 0.05). In Child-Pugh class A (n = 94), low-NLR had higher OS vs high-NLR (25.4 vs 12.2 months, P < 0.01). In Child-Pugh class B/C (n = 28), NLR did not have a significant effect on median OS (low- vs high-NLR: 6.7 vs 2.9 months, P = 0.2). Child-Pugh class acted as an effect modifier on MVA for NLR (P = 0.0124).
Conclusions: The NLR has a stronger impact as a prognostic marker in ICC over the PLR and SII. This survival effect is decreased in advanced liver disease.
Keywords: bile ducts; cholangiocarcinoma; intrahepatic; liver cirrhosis; lymphocytes; neutrophils; platelets.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no conflicts of interest to report. The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript. Hyun S. Kim served on Advisory boards for Boston Scientific and SIRTex.
The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis.HPB (Oxford). 2020 Apr 4:S1365-182X(20)30093-9. doi: 10.1016/j.hpb.2020.03.011. Online ahead of print. HPB (Oxford). 2020. PMID: 32265108
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.BMC Cancer. 2013 Jul 22;13:350. doi: 10.1186/1471-2407-13-350. BMC Cancer. 2013. PMID: 23876227 Free PMC article.
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Front Pharmacol. 2016 Oct 13;7:376. doi: 10.3389/fphar.2016.00376. eCollection 2016. Front Pharmacol. 2016. PMID: 27790145 Free PMC article.
Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.Medicine (Baltimore). 2020 Mar;99(10):e19405. doi: 10.1097/MD.0000000000019405. Medicine (Baltimore). 2020. PMID: 32150090
Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.Cell Physiol Biochem. 2017;44(3):967-981. doi: 10.1159/000485396. Epub 2017 Nov 27. Cell Physiol Biochem. 2017. PMID: 29179180 Review.
Cited by 1 article
Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection.World J Gastrointest Oncol. 2020 Apr 15;12(4):467-482. doi: 10.4251/wjgo.v12.i4.467. World J Gastrointest Oncol. 2020. PMID: 32368324 Free PMC article.
- Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(1 Suppl):171‐190. - PubMed
- Shaib Y, El‐Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115‐125. - PubMed
- Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII: IARC Scientific Publication No. 155I. Lyon: ARC Press; 2002.
- Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379(2):198‐205. - PubMed